Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery - 1 Nov 2009

Pu Xing-xiang, Deng Yan-hong, Xu Fei, Xiao Jian, Guo Hong-qiang, Huang He, Tian Ying, He You-jian, Lin Tong-yu

Abstract excerpt

OBJECTIVE: To explore the relationship between KRAS gene status and efficacy of Cetuximab (C225) combined with chemotherapy on advanced colorectal cancer in Chinese patients, and to evaluate the safety of C225. METHODS: From May 2006 to March 2009, 81 patients with advanced colorectal cancer received Cetuximab combined with chemotherapy were enrolled in this study. The rate of KRAS mutation and the relationship...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Cetuximab

Share to Colorectal Neoplasms

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 19921572

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients].PMID 19921572Read ↗

Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan.Semantic proximity Read ↗

Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: effect of KRAS mutation on treatment efficacy in Taiwanese patients.Semantic proximity Read ↗

[KRAS mutation test].Semantic proximity Read ↗

[Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].Semantic proximity Read ↗

[Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].Semantic proximity Read ↗

Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

Standard chemotherapy with cetuximab for treatment of colorectal cancer.Semantic proximity Read ↗

[KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese].Semantic proximity Read ↗

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.Semantic proximity Read ↗

Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature.Semantic proximity Read ↗

Letter to the editor: Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutation.Semantic proximity Read ↗

The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.